Literature DB >> 17964011

Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.

Audrey Ferrier-Rembert1, Robert Drillien, Bernard Meignier, Daniel Garin, Jean-Marc Crance.   

Abstract

It is now difficult to manufacture the first-generation smallpox vaccine, as the process could not comply with current safety and manufacturing regulations. In this study, a candidate non-clonal second-generation smallpox vaccine developed by Sanofi-Pasteur from the Lister strain has been assessed using a cowpox virus challenge in mice. We have observed similar safety, immunogenicity and protection (from disease and death) after a short or long interval following vaccination, as well as similar virus clearance post-challenge, with the second-generation smallpox vaccine candidate as compared to the traditional vaccine used as a benchmark.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17964011     DOI： 10.1016/j.vaccine.2007.09.050

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  8 in total

1.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

2.  Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.

Authors:  Maria Luiza G Medaglia; Nissin Moussatché; Andreas Nitsche; Pjotr Wojtek Dabrowski; Yu Li; Inger K Damon; Carolina G O Lucas; Luciana B Arruda; Clarissa R Damaso
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

3.  Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

Authors:  Aklile Berhanu; David S King; Stacie Mosier; Robert Jordan; Kevin F Jones; Dennis E Hruby; Douglas W Grosenbach
Journal:  Vaccine       Date:  2010-10-29       Impact factor: 4.169

Review 4.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 5.  The French Armed Forces Virology Unit: A Chronological Record of Ongoing Research on Orthopoxvirus.

Authors:  Déborah Delaune; Frédéric Iseni; Audrey Ferrier-Rembert; Christophe N Peyrefitte; Olivier Ferraris
Journal:  Viruses       Date:  2017-12-23       Impact factor: 5.048

6.  Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers.

Authors:  Philippe Bossi; Frédérick Gay; Imène Fouzai; Béhazine Combadière; Geneviève Brousse; Bénédicte Lebrun-Vignes; Jean-Marc Crance; Brigitte Autran; Daniel Garin
Journal:  PLoS One       Date:  2008-12-31       Impact factor: 3.240

7.  Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.

Authors:  Marsha S Russell; Sathya N Thulasi Raman; Caroline Gravel; Wanyue Zhang; Annabelle Pfeifle; Wangxue Chen; Gary Van Domselaar; David Safronetz; Michael Johnston; Simon Sauve; Lisheng Wang; Michael Rosu-Myles; Jingxin Cao; Xuguang Li
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

Review 8.  Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.

Authors:  Onur Kaynarcalidan; Sara Moreno Mascaraque; Ingo Drexler
Journal:  Biomedicines       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.